Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-Dehydroepiandrosterone (4-DHEA) is a synthetic 3β-hydroxy steroid and an isomer of the naturally occurring 5-dehydroepiandrosterone (DHEA). It is primarily utilized as a prohormone within the dietary supplement industry, where it is marketed for its potential to increase muscle mass and strength. Structurally, 4-DHEA differs from DHEA by the position of its double bond at the 4-position rather than the 5-position. Upon ingestion, 4-DHEA undergoes a two-step enzymatic conversion: it is first converted into androstenedione by 3β-hydroxysteroid dehydrogenase (3β-HSD) and subsequently into testosterone by 17β-hydroxysteroid dehydrogenase (17β-HSD). While it is widely available as a nutraceutical, it is not an FDA-approved pharmaceutical for any clinical indication and is often subject to regulation or bans by athletic organizations due to its anabolic properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-dehydroepiandrosterone.